---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-011475"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:27:55.046609+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics appoints Douglas Manion as President and COO effective August 1, 2022

## Summary
- Douglas Manion appointed President and COO effective August 1, 2022; Neal Walker remains CEO.
- Receives annual base salary of $490,000, target annual bonus of 40% of salary.
- Granted stock options for 217,800 shares at $13.62 exercise price and RSU award for 62,300 shares.
- Equity awards vest over four years; severance includes 12 months base salary plus COBRA if terminated without cause.
- Previously EVP R&D at Arena Pharmaceuticals and held leadership roles at BMS.

## SEC filing metadata
- accession: 0001558370-22-011475
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/acrs-20220801x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-011475
- JSON: https://secwatch.observer/filing/0001558370-22-011475.json
- Plain text: https://secwatch.observer/filing/0001558370-22-011475.txt

## Key facts
- Executive change
  Douglas Manion was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: appointed Douglas Manion, M.D., FRCP (C), as the Company’s President and Chief Operating Officer effective August 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm
- Executive change
  Neal Walker changed role as President at Aclaris Therapeutics, Inc..
  - Action: no longer serve as
  - Role: President
  source text: Neal Walker will no longer serve as the Company’s President, but will continue to serve as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.